Published in final edited form as:

Bipolar Disord. 2015 May ; 17(3): 248–256. doi:10.1111/bdi.12260.

Longer lithium exposure is associated with better white matter integrity in older adults with bipolar disorder

Ariel G. Gildengers, M.D.^{*1}, Meryl A. Butters, Ph.D.¹, Howard J. Aizenstein, M.D., PH.D.¹, Megan M. Marron, B.S.², James Emanuel, B.S.¹, Stewart J. Anderson, Ph.D.², Lisa A. Weissfeld, Ph.D.², James T. Becker, Ph.D.¹, Oscar L. Lopez, M.D.³, Benoit H. Mulsant, M.D.⁴, and Charles F. Reynolds III, M.D.¹

¹University of Pittsburgh School of Medicine, Department of Psychiatry, Pittsburgh, PA, USA

²University of Pittsburgh Graduate School of Public Health, Department of Biostatistics, Pittsburgh, PA, USA

³University of Pittsburgh School of Medicine, Department of Neurology, Pittsburgh, PA, USA

⁴Centre for Addiction and Mental Health and the University of Toronto, Department of Psychiatry, Toronto, ON, Canada

Abstract

Background—Bipolar Disorder (BD) is associated with cognitive dysfunction and structural brain abnormalities. In human and non-human studies, lithium has been related to neuroprotective and neurotrophic effects. We explored whether lithium treatment is related to better brain integrity and cognitive function in older adults with BD.

Methods—We examined cognitive and neuroimaging data in 58 individuals with BD mean (SD) age 64.5 (9.8) years and 21 mentally healthy comparators (“controls”) of similar age and education. Subjects received comprehensive neurocognitive assessment and structural brain imaging, examining total gray matter volume, overall white matter integrity (fractional anisotropy), and total white matter hyperintensity (WMH) burden.

Results—In comparison to controls, subjects with BD had worse overall cognitive performance, lower total gray matter volume, and lower white matter integrity. Among BD subjects, longer duration of lithium treatment was related to higher white matter integrity after controlling for age and vascular disease burden, but not with better cognitive performance.

*Corresponding author: Dr. Gildengers, 3811 O'Hara Street, Pittsburgh, PA 15213, USA. Phone 412-246-6002; Fax 412-246-6030. arielg@pitt.edu.

Disclosures: The following disclosures within the past 5 years are reported in connection with the manuscript:

1. Dr. Butters has received payment from Northstar Neuroscience and Medtronic for providing neuropsychological assessment services to clinical trials and from Fox Learning Systems (via NIH-funded SBIR) for computerized test development. She is currently a consultant for GlaxoSmithKline, for whom she is interpreting the results of neuropsychological evaluations.
2. Dr. Gildengers has received research support from GlaxoSmithKline for an investigator-initiated study.
3. Dr. Mulsant has received research support in the form of pharmaceutical supplies for his NIH sponsored research from Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, and Wyeth
4. Dr. Reynolds has received research support in the form of pharmaceutical supplies for his NIH sponsored research from Bristol-Myers Squibb, Eli Lilly and Company, Forest, and Pfizer,
5. All other authors report no financial relationships with commercial interests.

Conclusions—Lithium treatment appears to be related to better brain integrity in older individuals with BD, in particular in those who take it long-term. While intriguing, these findings need to be confirmed in a larger sample.

Keywords

Lithium; Bipolar Disorder; Neuroprotection

Introduction

Bipolar disorder (BD) afflicts over 100 million individuals worldwide.(1) While BD is costly and potentially devastating, not all individuals with BD experience a profoundly debilitating course or die prematurely.(2) Some of the heterogeneity in outcome may be related to the benefits of lithium treatment.(3, 4) In particular, lithium has been shown to reduce risk for suicide.(5) Lithium has also been associated with neurogenesis in the hippocampus,(6) up-regulation of important neurotrophic factors such as B-cell lymphoma 2 (Bcl-2) and brain-derived neurotrophic factor (BDNF),(7) and inhibition of glycogen synthase kinase 3 (GSK-3), a critical regulator of amyloid precursor protein involved in the development of amyloid- β plaques as well as hyper-phosphorylation of tau involved with neurofibrillary tangle formation and Alzheimer's disease (AD).(8) GSK-3 is also involved in the regulation of brain myelination.(9) The beneficial effects of lithium are supported by molecular and cellular data,(10) mouse and human data,(11-15) and epidemiologic data suggesting that lithium may decrease incidence of dementia.(16)

There is a large literature focused on BD and cognitive dysfunction or neuroimaging abnormalities in middle-aged and younger adults.(17, 18) In brief, BD is associated with impairments in attention, working memory, information-processing speed, and executive dysfunction.(19) Neuroimaging abnormalities include enlarged ventricles, increased periventricular white matter hyperintensities (WMHs) suggestive of vascular disease burden, and lower fractional anisotropy (FA) -- a measure of white matter tract integrity.(20, 21) Few studies have integrated neurocognitive with neuroimaging findings.(17, 18) In one such study, reductions in temporal lobe gray matter were correlated with impaired cognitive function and with the number of mood episodes over four years.(22) In mentally healthy older individuals, higher WMH burden has been associated with decreased information processing speed.(23)

Long-term treatment with lithium may affect brain structure, bringing about increased total gray matter, hippocampal and amygdala volumes, and enhanced white matter tract integrity (i.e., higher FA).(24, 25) It appears that lithium's effect on gray matter volume is larger than the effect of other mood stabilizers.(26, 27) However, this requires confirmation using controlled evaluation. Further, lithium binds to cholinergic receptors and it may thus negatively affect cognition.(28) However, the literature regarding lithium's effects on cognitive function is mixed. A meta-analysis of 12 studies involving 276 subjects who had taken lithium for a mean of 3.9 years, concluded that lithium had only few and minor negative effects on cognition.(29) These studies raise the possibility that lithium may not provide cognitive enhancement, but may protect from cognitive deterioration over the long-

term. While in contrast to lithium, data suggest that atypical antipsychotics negatively affect brain structures.(30-33)

Several studies have examined cognitive dysfunction and neuroimaging abnormalities in older adults with BD.(34-38) A benefit of studying older adults with BD is the opportunity to examine the long-term effects of medications. For example, Beyer and colleagues identified gray matter volume deficits in the inferior frontal lobe in BD in subjects (n=36) with mean (SD) age 58.2 (7.8) years compared to mentally healthy control subjects (n=29) of the same age.(39) They also found that the use of lithium was associated with increased hippocampal volume.

Over the past several years, we have been following a cohort of older adults with BD, of whom a subset has been treated with lithium for 10 or more years. This cohort provides an opportunity to examine whether long-term lithium exposure is related to better brain health, including better cognitive function. We examined the relationships among long-term lithium exposure, brain integrity, and cognitive function. Our hypotheses were that in individuals with BD, longer exposure to lithium would be associated with (a) better overall cognitive function and (b) better brain integrity as indexed with higher total gray matter, higher fractional anisotropy (FA), and lower white matter hyperintensity burden. To our knowledge, this is the first examination of the relationship among lithium use, cognitive function, and brain structure in older adults with BD. If long-term use of lithium has a meaningful impact on cognitive function or brain integrity, we would expect to see these effects in older adults with BD who are more likely to experience cognitive impairment or to show brain abnormalities and who have typically been taking lithium over longer period of time. In these analyses, we examined subjects based on overall lifetime lithium exposure, regardless of whether they were currently taking lithium. In addition, we selected overall, rather than regional, measures of brain integrity to examine generalized effects of lithium treatment and to minimize the number of statistical comparisons. In our regression analyses, we controlled for factors that influence brain integrity, such as age and vascular disease burden.(40-42) Given the evidence that antipsychotics can have negative effects on brain structures, we conducted exploratory analyses examining the influence of antipsychotics on brain integrity.

Methods

Subjects

Individuals with BD I or II were recruited in the outpatient clinics and inpatient units of Western Psychiatric Institute and Clinic or referred from the community. Comparator (“control”) subjects were individuals with no psychiatric or neurologic history selected to make the groups similar in age, education, and cardiovascular disease burden; they were recruited through health fairs, advertisements in local papers, and ongoing projects studying the relationship between late-life mood disorders and cognitive function (43, 44). In addition, comparator subjects with general medical burden comparable to subjects with BD were recruited in primary care practices (45). All subjects provided written informed consent, as required by the Institutional Review Board at the University of Pittsburgh.

Inclusion criteria required

age 50 years or older; clinical euthymia for four weeks preceding neuropsychological (NP) assessment with scores of 10 or less on both the 17-item Hamilton Rating Scale for Depression (HRSD) (46) and the Young Mania Rating Scale (YMRS) (47) at the time of assessment; ability to comprehend and speak English fluently; corrected visual ability to read newspaper headlines; and hearing capacity adequate to respond to a raised conversational voice.

Exclusion criteria were

pre-existing history of dementia or neurologic disorder affecting the central nervous system (for example, Parkinson's disease, traumatic brain injury, or multiple sclerosis); electro-convulsive therapy within the past six months; and substance abuse or dependence within the past twelve months. For this report, we focused on subjects who had completed both neuroimaging and neurocognitive assessment.

Diagnosis and Treatment

Diagnosis was established by the Structured Clinical Interview for Axis I DSM-IV Disorders (SCID-IV) administered by trained clinicians. The majority of subjects were receiving treatment in our university-based clinics. In these clinics, the goals of the pharmacotherapy intervention for BD have been to maximize the appropriate use of lithium or divalproex, either singly or in combination, to achieve remission of acute mood episodes, maintain euthymia, and limit adjunctive anti-psychotic or antidepressant medication.(48)

Recruitment

From January 1, 2010 through December 31, 2012, 209 subjects signed consent, and 166 of those who met basic eligibility requirements underwent assessment with the Structured Clinical Interview for DSM-IV-TR (SCID). One hundred subjects with BD and 38 controls met all eligibility criteria, enrolled in the study, and completed baseline testing.

Imaging was completed on 62 subjects with BD and 21 controls. Reasons for not completing the MRI included refusal (11 with BD, 8 controls), safety or physical reasons (e.g., metal fragments; 14 with BD, 3 controls), clinical reasons (e.g., claustrophobia; 9 with BD, 3 controls), and scheduling reasons (4 with BD, 3 controls). Four subjects with BD were excluded from this analysis: one had his psychiatric diagnosis revised to schizoaffective disorder following baseline testing; one because of the identification of an unknown congenital brain abnormality; one because of severe motion artifacts during FLAIR acquisition; and one because the FLAIR was not obtained due to a technical error. Thus, 58 subjects with BD and 21 controls were included in this analysis. The 58 subjects with BD who had complete MRI data did not differ significantly from the subjects with BD who did not have MRI scans on any of the demographic or clinical measures.

Clinical Measures

General medical burden was assessed with the Cumulative Illness Rating Scale-Geriatric and vascular disease burden with the Framingham Stroke Risk Profile (FSRP).(49, 50) We

obtained information on pharmacotherapy exposure from interviewing the subjects, their family members, and all available records. Information was gathered on duration of lithium exposure (years). While some information was available on mean serum lithium levels, it was insufficient to include in our analyses. Duration of antipsychotic exposure in most subjects was substantially shorter than lithium exposure with much less reliable information available on its duration. Consequently, information on exposure was limited to whether a subject had taken an antipsychotic.

Neurocognitive Assessment

As described in a previous report, NP assessment encompassed 21 well-established and validated individual tests measuring multiple cognitive domains that were organized into domain scores, based on a factor analysis.(51) Aspects of executive function were distributed throughout all domains, but they predominantly loaded with information processing speed. The domains were information processing speed/executive, memory, language, and visuospatial ability. A global score was determined based on all 21 individual tests. We normalized raw scores for all individual tests using the baseline distribution of the mentally healthy comparators (i.e., comparators' performance on any test has a mean of 0 and a standard deviation of 1).(51)

Neuroimaging

MR brain imaging was performed in the University of Pittsburgh MR Research Center using a Siemens 3 Tesla TIM Trio scanner, with a 12-channel, phased-array head coil. The following oblique-axial series oriented to the plane connecting the anterior and posterior commissures were acquired to screen subjects for unexpected pathology and evaluate for brain tissue volume loss and white matter hyperintensities: 1) T1-weighted, 2) fast spin-echo T2-weighted, 3) fast spin-echo proton density-weighted, and 4) T2-weighted interleaved fast FLuid-Attenuated Inversion Recovery (FLAIR). A volumetric Magnetization Prepared Rapid Gradient Echo (MPRAGE) sequence was performed in the coronal plane. This sequence yields 176 continuous slices, maximizes contrast among gray matter, white matter, and cerebrospinal fluid, and provides high-resolution delineation of cortical and subcortical structures. Additionally, 12-30 direction Diffusion Tensor Images were acquired using the following parameters: 3mm slice thickness, 128×128mm resolution, 256×256mm FOV, 5300ms TR, 2500ms TI, 88ms TE, and 90° flip angle in the axial plane. TR=6400 ms, TE=89 ms, slice thickness=2.5 mm, number of slices=52, b=0, and 850, s/mm², number of averages=2, GRAPPA2, resolution 2.5×2.5×2.5mm.

MR imaging: Automated Labeling Pathway

To determine regional gray and white brain volumes, Aizenstein and colleagues at the Geriatric Psychiatry Neuroimaging (GPN) Lab (www.gpn.pitt.edu) developed a procedure referred to as the Automated Labeling Pathway (ALP), which has been previously described.(52)

MR imaging of WMHs

FLAIR images were used for WMH quantification and localization. WMH quantification was done with automated method developed in the GPN Lab, which uses a fuzzy connected algorithm to segment the WMH(53) and atlas-based segmentation to localize the WMH into the anatomical space.(54) This method enables different thresholds for different WMH clusters and avoids a single cut-off threshold for the whole brain or brain slice. This method generates total WMH volumes, as well as WMH volumes for each frontal and subcortical white matter tract defined in the Johns Hopkins White Matter Atlas.(55)

MR imaging: DTI Labeling Pathway

The processing pathway uses Tract Based Spatial Statistics (56) to generate a voxel-wise cross-registered skeletonized FA maps in MNI space, and uses ALP, and WMH quantification and localization to generate white matter tract-specific ROI summary scores for normal appearing white matter (i.e., excluding WMH on the T2-FLAIR).

Statistical Analyses

We used descriptive statistics (mean and standard deviation or count and %) to characterize the subjects with BD versus the mentally healthy comparators and antipsychotic exposure within the BD subjects. We compared two groups using a t-test or a Wilcoxon exact test for continuous measures. We used a Chi-square test or a Fisher's exact test to examine categorical variables.

We used Pearson correlations to examine the association of global cognitive function with other measures in the subjects with BD. We entered variables that were correlated ($p < 0.10$) with global cognitive function in a regression model, using both backward and forward stepwise regression to obtain a stable parsimonious model predicting global cognition in subjects with BD. We used the same process to obtain a stable model for whole brain FA and WMH in subjects with BD.

Results

Subjects with BD and mentally healthy comparators had similar age and education. Subjects with BD had higher medical comorbidity (CIRS-G), but comparable cardiovascular disease burden and Framingham (FSRP) scores (see Table 1). Subjects with BD performed below mentally healthy comparators when looking at overall cognitive function (global score) and within specific domains with language ability being least affected and information processing speed/executive (speed/executive) function most affected (Table 1). Subjects with BD had lower total gray matter volume, lower white matter integrity (FA), but comparable amounts of WMH burden (Table 1).

Of the 58 subjects with BD, 33 had taken lithium and 25 had minimal (< 1 year) or no exposure. The 33 subjects with lithium exposure had mean (SD) lithium treatment of 13.8 (12.4) years (median=11, min=1, max=43). There were no statistically significant differences between the 33 BD subjects with lithium exposure versus minimal exposure in age, gender, race, education, mood, and medical burden, including vascular burden (FSRP).

Age, education, race (Caucasian versus non-Caucasian), FSRP, total gray matter, white matter integrity (FA), and WMH were all correlated with global cognitive function ($p < 0.10$; Table 2). Duration of lithium treatment was not significantly associated with global cognitive function. In the stepwise regression, higher white matter integrity (FA) and more years of education were significantly associated with better global cognition (Table 3).

Age and FSRP, but not duration of lithium treatment, were correlated with total gray matter volume (Table 2).

Duration of lithium treatment, age, education, FSRP, race (Caucasian versus non-Caucasian), and CIRS-G were significantly associated with white matter integrity (FA) (Table 2). In the stepwise regression, longer duration of lithium treatment and younger age were significantly associated with higher FA (Table 3).

Lithium duration, age, education, FSRP, and CIRS-G were also significantly associated with WMH burden (Table 2). In the stepwise regression, only younger age was significantly associated with lower WMH burden (Table 3).

Subjects with antipsychotic exposure are presented in supplementary information (Table S1). Note that duration of antipsychotic exposure in most subjects was substantially shorter than lithium exposure with much less reliable information available on its duration. Information on exposure was limited to whether a subject had taken an antipsychotic. There were 26 subjects who had both lithium and antipsychotic exposure, 19 subjects with antipsychotic exposure and no lithium exposure, 7 with lithium and no antipsychotic exposure, and 6 with neither lithium nor antipsychotic exposure. Exploratory analyses of antipsychotic exposure revealed no differences in cognitive function and brain integrity between those with antipsychotic exposure versus not (see supplementary Table S2). The only significant difference between subjects with antipsychotic exposure versus not was age ($t[56]=3.0$; $p=0.05$). Those who were treated with at least one antipsychotic were younger than those never treated with an antipsychotic.

Discussion

We found that long-term lithium exposure is related to indices of better brain integrity. While our findings are intriguing, they need to be confirmed in a larger sample given various limitations. Foremost, our N is small and our examination is cross-sectional with lithium exposure determined retrospectively. Quantifying long-term lithium exposure in older adults can be imprecise. If it were available, more accurate quantification of lithium exposure, including adherence, dosage, stoppage, etc., would enhance the power to detect differences associated with it. Further, quantification of antipsychotic exposure using chlorpromazine equivalents would help account for antipsychotic effect on cognition and measures of brain integrity. Additional limitations include concerns about the generalizability of findings derived from patients treated in an academic medical center that prioritizes lithium as a first-line agent as well as survivorship bias.

Notwithstanding these limitations, our results are congruent with several human studies that have reported a neuroprotective effect of lithium in older persons (15, 57-60). Terao and

colleagues examined the clinical records of 1,423 outpatients, comparing older patients (n =30; mean (SD) age: 68.4 (5.2) years) with a history of taking lithium and matched controls (n=20; 70.3 (6.4) years). The patients treated with lithium had significantly higher Mini Mental State Exam scores.(61) Nunes and colleagues compared the prevalence of Alzheimer's disease (AD) in 66 older patients with BD treated with lithium chronically and 48 similar patients with BD without recent treatment with lithium. The mean (SD) age was 67.4 (4.7) years and AD was diagnosed in 3 (5%) of the patients on lithium versus 16 (33%) of those who were not on lithium, which was significantly lower.(60) When lithium was given to 71 patients with mild AD (mean (SD) age: 68.6 (7.8) years) in a single-blind, placebo-controlled, multi-center, no treatment effect on GSK-3 activity or CSF-based biomarker concentrations was observed over 10 weeks.(59)

Lithium was not associated with either a worsening or an improvement in global cognitive performance as measured by the ADAS-Cog subscale. However, in a subset of 27 subjects, lithium was associated with increased serum levels of BDNF and there was an improvement in ADAS-Cog subscale in those with increased BDNF(15, 62). Similarly, in a one-year placebo-controlled trial in 45 patients with amnesic mild cognitive impairment age 60 years and older, lithium reduced cognitive decline and CSF concentration of phosph-tau.(58)

Taken together, the human studies summarized above and our data suggest that lithium may enhance brain integrity positively when it is taken long-term and possibly early on. In particular, lithium might improve myelination by acting on neuroglial signaling pathways, such as GSK-3.(9) Given our intriguing findings and the findings of others summarized above, we suggest as a possible next step in the evaluation of the benefits of lithium treatment on brain health, a short-term (one-year) prospective randomized controlled trial of add-on lithium versus placebo in older adults with BD who have had minimal recent lithium exposure, evaluating both cognitive and brain imaging outcomes as well as measuring biomarkers (e.g., BDNF, GSK-3 activity, and inflammatory markers). Depending on the outcome of a short-term study, a larger, longer-term study may then be undertaken. If such future studies confirm the neuroprotective effect of lithium in BD, this may alter long-term treatment options in favor of lithium. Additionally, these studies may also suggest a role for lithium treatment for neuroprotection in individuals without BD who are at high risk for neurodegeneration.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors thank Ms. Michelle Zmuda for the recruitment of control subjects and coordination of all neuropsychological assessments as well as Ms. Colleen Nable for efforts in processing the neuroimaging data presented in this report.

Funding Sources: Supported in part by National Institute of Mental Health grants R01 MH084921 (AGG), R01 MH076079 (HJA) P30 MH90333 (CFR), and the UPMC Endowment in Geriatric Psychiatry (CFR)

References

1. Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. *Archives of general psychiatry*. 2011; 68:241–51. [PubMed: 21383262]
2. Kleinman L, Lowin A, Flood E, Gandhi G, Edgell E, Revicki D. Costs of bipolar disorder. *PharmacoEconomics*. 2003; 21:601–22. [PubMed: 12807364]
3. Goodwin, FK.; Jamison, KR. *Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression*. New York: Oxford; 2007.
4. Malhi GS, Tanious M, Das P, Coulston CM, Berk M. Potential mechanisms of action of lithium in bipolar disorder. Current understanding. *CNS Drugs*. 2013; 27:135–53. [PubMed: 23371914]
5. Tondo L, Baldessarini RJ. Long-term lithium treatment in the prevention of suicidal behavior in bipolar disorder patients. *Epidemiol Psichiatr Soc*. 2009; 18:179–83. [PubMed: 20034193]
6. van Erp TG, Thompson PM, Kieseppa T, Bearden CE, Marino AC, Hoftman GD, et al. Hippocampal morphology in lithium and non-lithium-treated bipolar I disorder patients, nonbipolar co-twins, and control twins. *Hum Brain Mapp*. 2012; 33:501–10. [PubMed: 21455943]
7. Schloesser RJ, Martinowich K, Manji HK. Mood-stabilizing drugs: mechanisms of action. *Trends Neurosci*. 2012; 35:36–46. [PubMed: 22217451]
8. Freland L, Beaulieu JM. Inhibition of GSK3 by lithium, from single molecules to signaling networks. *Front Mol Neurosci*. 2012; 5:14. [PubMed: 22363263]
9. Bartzokis G. Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments. *Neuropharmacology*. 2012; 62:2137–53. [PubMed: 22306524]
10. Quiroz JA, Gould TD, Manji HK. Molecular effects of lithium. *Mol Interv*. 2004; 4:259–72. [PubMed: 15471909]
11. Moore GJ, Bebchuk JM, Hasanat K, Chen G, Seraji-Bozorgzad N, Wilds IB, et al. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects? *Biol Psychiatry*. 2000; 48:1–8. [PubMed: 10913502]
12. Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK. Lithium-induced increase in human brain grey matter. *Lancet*. 2000; 356:1241–2. [PubMed: 11072948]
13. Bachmann RF, Wang Y, Yuan P, Zhou R, Li X, Alesci S, et al. Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage. *The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum*. 2009; 12:805–22.
14. Chen G, Zeng WZ, Yuan PX, Huang LD, Jiang YM, Zhao ZH, et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. *Journal of neurochemistry*. 1999; 72:879–82. [PubMed: 9930766]
15. Diniz BS, Machado-Vieira R, Forlenza OV. Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders. *Neuropsychiatric disease and treatment*. 2013; 9:493–500. [PubMed: 23596350]
16. Kessing LV, Sondergard L, Forman JL, Andersen PK. Lithium Treatment and Risk of Dementia. *Archives of general psychiatry*. 2008; 65:1331–5. [PubMed: 18981345]
17. Bearden CE, Woogen M, Glahn DC. Neurocognitive and neuroimaging predictors of clinical outcome in bipolar disorder. *Curr Psychiatry Rep*. 2010; 12:499–504. [PubMed: 20839077]
18. Lim CS, Baldessarini RJ, Vieta E, Yucel M, Bora E, Sim K. Longitudinal neuroimaging and neuropsychological changes in bipolar disorder patients: review of the evidence. *Neuroscience and biobehavioral reviews*. 2013; 37:418–35. [PubMed: 23318228]
19. Bourne C, Aydemir O, Balanza-Martinez V, Bora E, Brissos S, Cavanagh JT, et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. *Acta Psychiatr Scand*. 2013; 128:149–62. [PubMed: 23617548]
20. Kempton MJ, Geddes JR, Ettinger U, Williams SCR, Grasby PM. Meta-analysis, Database, and Meta-regression of 98 Structural Imaging Studies in Bipolar Disorder. *Archives of general psychiatry*. 2008; 65:1017–32. [PubMed: 18762588]

21. Schneider MR, DelBello MP, McNamara RK, Strakowski SM, Adler CM. Neuroprogression in bipolar disorder. *Bipolar Disord.* 2012; 14:356–74. [PubMed: 22631620]
22. Moorhead TWJ, McKirdy J, Sussmann JED, Hall J, Lawrie SM, Johnstone EC, et al. Progressive Gray Matter Loss in Patients with Bipolar Disorder. *Biological Psychiatry.* 2007; 62:894–900. [PubMed: 17617385]
23. Gunning-Dixon FM, Raz N. The cognitive correlates of white matter abnormalities in normal aging: a quantitative review. *Neuropsychology.* 2000; 14:224–32. [PubMed: 10791862]
24. Macritchie KA, Lloyd AJ, Bastin ME, Vasudev K, Gallagher P, Eyre R, et al. White matter microstructural abnormalities in euthymic bipolar disorder. *The British journal of psychiatry : the journal of mental science.* 2010; 196:52–8. [PubMed: 20044661]
25. Hafeman DM, Chang KD, Garrett AS, Sanders EM, Phillips ML. Effects of medication on neuroimaging findings in bipolar disorder: an updated review. *Bipolar Disord.* 2012; 14:375–410. [PubMed: 22631621]
26. Germana C, Kempton MJ, Sarnicola A, Christodoulou T, Haldane M, Hadjulis M, et al. The effects of lithium and anticonvulsants on brain structure in bipolar disorder. *Acta Psychiatr Scand.* 2010; 122:481–7. [PubMed: 20560901]
27. Foland LC, Altshuler LL, Sugar CA, Lee AD, Leow AD, Townsend J, et al. Increased volume of the amygdala and hippocampus in bipolar patients treated with lithium. *Neuroreport.* 2008; 19:221–4. [PubMed: 18185112]
28. Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, Mahmoud RA, et al. Anticholinergic Activity of 107 Medications Commonly Used by Older Adults. *J Am Geriatr Soc.* 2008
29. Wingo AP, Wingo TS, Harvey PD, Baldessarini RJ. Effects of lithium on cognitive performance: a meta-analysis. *The Journal of clinical psychiatry.* 2009; 70:1588–97. [PubMed: 19689922]
30. Thompson PM, Bartzokis G, Hayashi KM, Klunder AD, Lu PH, Edwards N, et al. Timelapse mapping of cortical changes in schizophrenia with different treatments. *Cerebral cortex.* 2009; 19:1107–23. [PubMed: 18842668]
31. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. *Archives of general psychiatry.* 2011; 68:128–37. [PubMed: 21300943]
32. Vernon AC, Crum WR, Lerch JP, Chege W, Natesan S, Modo M, et al. Reduced Cortical Volume and Elevated Astrocyte Density in Rats Chronically Treated with Antipsychotic Drugs-Linking Magnetic Resonance Imaging Findings to Cellular Pathology. *Biol Psychiatry.* 2013
33. Vernon AC, Natesan S, Modo M, Kapur S. Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. *Biol Psychiatry.* 2011; 69:936–44. [PubMed: 21195390]
34. Samame C, Martino DJ, Strejilevich SA. A quantitative review of neurocognition in euthymic late-life bipolar disorder. *Bipolar Disord.* 2013
35. Delaloye C, Moy G, de Bilbao F, Weber K, Baudois S, Haller S, et al. Longitudinal analysis of cognitive performances and structural brain changes in late-life bipolar disorder. *International journal of geriatric psychiatry.* 2011; 26:1309–18. [PubMed: 21394788]
36. Delaloye C, de Bilbao F, Moy G, Baudois S, Weber K, Campos L, et al. Neuroanatomical and neuropsychological features of euthymic patients with bipolar disorder. *Am J Geriatr Psychiatry.* 2009; 17:1012–21. [PubMed: 20104058]
37. Tamashiro JH, Zung S, Zanetti MV, de Castro CC, Vallada H, Busatto GF, et al. Increased rates of white matter hyperintensities in late-onset bipolar disorder. *Bipolar Disord.* 2008; 10:765–75. [PubMed: 19032708]
38. Wijeratne C, Sachdev S, Wen W, Piguet O, Lipnicki DM, Malhi GS, et al. Hippocampal and amygdala volumes in an older bipolar disorder sample. *Int Psychogeriatr.* 2013; 25:54–60. [PubMed: 22929183]
39. Beyer JL, Kuchibhatla M, Payne ME, Moo-Young M, Cassidy F, Macfall J, et al. Hippocampal volume measurement in older adults with bipolar disorder. *Am J Geriatr Psychiatry.* 2004; 12:613–20. [PubMed: 15545329]

40. Farr SA, Yamada KA, Butterfield DA, Abdul HM, Xu L, Miller NE, et al. Obesity and hypertriglyceridemia produce cognitive impairment. *Endocrinology*. 2008; 149:2628–36. [PubMed: 18276751]
41. Wolf PA, Beiser A, Elias MF, Au R, Vasan RS, Seshadri S. Relation of obesity to cognitive function: importance of central obesity and synergistic influence of concomitant hypertension. The Framingham Heart Study. *Current Alzheimer research*. 2007; 4:111–6. [PubMed: 17430232]
42. Sabia S, Kivimaki M, Shipley MJ, Marmot MG, Singh-Manoux A. Body mass index over the adult life course and cognition in late midlife: the Whitehall II Cohort Study. *The American journal of clinical nutrition*. 2009; 89:601–7. [PubMed: 19073790]
43. Butters MA, Whyte EM, Nebes RD, Begley AE, Dew MA, Mulsant BH, et al. The Nature and Determinants of Neuropsychological Functioning in Late-Life Depression. *Archives of general psychiatry*. 2004; 61:587–95. [PubMed: 15184238]
44. Bhalla RK, Butters MA, Becker JT, Houck PR, Snitz BE, Lopez OL, et al. Patterns of Mild Cognitive Impairment After Treatment of Depression in the Elderly. *American Journal of Geriatric Psych*. 2009; 17:308–16.10.1097/JGP.0b013e318190b8d8
45. Reynolds CF 3rd, Butters MA, Lopez O, Pollock BG, Dew MA, Mulsant BH, et al. Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. *Archives of general psychiatry*. 2011; 68:51–60. [PubMed: 21199965]
46. Hamilton M. Development of a rating scale for primary depressive illness. *British Journal of Social & Clinical Psychology*. 1967; 6:278–96. [PubMed: 6080235]
47. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. *British Journal of Psychiatry*. 1978; 133:429–35. [PubMed: 728692]
48. Gildengers AG, Mulsant BH, Begley AE, McShea M, Stack JA, Miller MD, et al. A Pilot Study of Standardized Treatment in Geriatric Bipolar Disorder. *Am J Geriatr Psychiatry*. 2005; 13:319–23. [PubMed: 15845758]
49. Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. *Psychiatry research*. 1992; 41:237–48. [PubMed: 1594710]
50. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. *Stroke; a journal of cerebral circulation*. 1991; 22:312–8.
51. Gildengers AG, Chisholm D, Butters MA, Anderson SJ, Begley A, Holm M, et al. Two-year course of cognitive function and instrumental activities of daily living in older adults with bipolar disorder: evidence for neuroprogression? *Psychological medicine*. 2012:1–11.
52. Rej S, Butters MA, Aizenstein HJ, Begley A, Tsay J, Reynolds CF 3rd, et al. Neuroimaging and neurocognitive abnormalities associated with bipolar disorder in old age. *International journal of geriatric psychiatry*. 2014; 29:421–7. [PubMed: 24006234]
53. Wu M, Rosano C, Butters M, Whyte E, Nable M, Crooks R, et al. A fully automated method for quantifying and localizing white matter hyperintensities on MR images. *Psychiatry research*. 2006; 148:133–42. [PubMed: 17097277]
54. Wu M, Rosano C, Lopez-Garcia P, Carter CS, Aizenstein HJ. Optimum template selection for atlas-based segmentation. *Neuroimage*. 2007; 34:1612–8. [PubMed: 17188896]
55. Mori, S.; Crain, BJ. MRI atlas of human white matter. 1st. Amsterdam ; Boston: Elsevier; 2005.
56. Smith SM, Jenkinson M, Johansen-Berg H, Rueckert D, Nichols TE, Mackay CE, et al. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. *Neuroimage*. 2006; 31:1487–505. [PubMed: 16624579]
57. Macdonald A, Briggs K, Poppe M, Higgins A, Velayudhan L, Lovestone S. A feasibility and tolerability study of lithium in Alzheimer's disease. *International journal of geriatric psychiatry*. 2008; 23:704–11. [PubMed: 18181229]
58. Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-modifying properties of long-term lithium treatment for amnesic mild cognitive impairment: randomised controlled trial. *The British journal of psychiatry : the journal of mental science*. 2011; 198:351–6. [PubMed: 21525519]

59. Hampel H, Ewers M, Burger K, Annas P, Mortberg A, Bogstedt A, et al. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. *The Journal of clinical psychiatry*. 2009; 70:922–31. [PubMed: 19573486]
60. Nunes PV, Forlenza OV, Gattaz WF. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. *The British Journal of Psychiatry*. 2007; 190:359–60. [PubMed: 17401045]
61. Terao T, Nakano H, Inoue Y, Okamoto T, Nakamura J, Iwata N. Lithium and dementia: a preliminary study. *Progress in neuro-psychopharmacology & biological psychiatry*. 2006; 30:1125–8. [PubMed: 16753246]
62. Leyhe T, Eschweiler GW, Stransky E, Gasser T, Annas P, Basun H, et al. Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease. *Journal of Alzheimer's disease : JAD*. 2009; 16:649–56.

Table 1
Baseline comparison between of subjects with BD and mentally healthy comparators

	Subjects with BD Mean (SD) or %(N) [n if reduced sample]	Controls Mean(SD) or %(N) [n if reduced sample]	Statistical test comparing BD subjects with BD and controls
N	58	21	
Age	64.5 (9.8)	65.6 (7.5)	t(77)=-0.48, p=0.63
%Female	70.7 (N=41)	52.4 (N=11)	Chi-sq(1)=2.3, p=0.13
% White	87.9 (N=51)	90.5 (N=19)	Fisher's Exact p=0.99
Education (years)	14.9 (3.2)	15.6 (2.9)	Wilcoxon Test p=0.49
YMRS score	2.40 (2.0)	0.381 (0.67)	Wilcoxon Test p<0.0001
HDRS 17-item score	4.05 (2.7)	1.38 (1.4)	Wilcoxon Test p<0.0001
Framingham Stroke Risk Profile *	0.109 (0.11)	0.075 (0.06)	t(77)=1.1, p=0.28
Cumulative Illness Rating Scale: Total	8.09 (3.2)	5.52 (3.6)	t(77)=3.0, p=0.003
Count	5.31 (2.0)	3.71 (2.3)	t(77)=3.0, p=0.003
Cognitive Domains: Global	-0.823 (1.2)	0.132 (0.44)	Wilcoxon Test p<0.0001
Visual	-0.758 (0.94)	0.088 (0.51)	t(64.9 [†])=-5.1, p<0.0001
Memory	-0.677 (0.90)	0.024 (0.60)	t(53.9 [†])=-4.0, p=0.0002
Language	-0.454 (0.94) [n=57]	0.198 (0.66)	t(76)=-2.9, p=0.005
Speed/Executive	-1.16 (2.6)	0.176 (0.48)	Wilcoxon Test p<0.0001
Imaging: Total Gray Matter Volume (normalized)	32.2 (4.1)	34.2 (3.1)	t(77)=-2.1, p=0.04
Overall White Matter Integrity (Fractional Anisotropy)	0.369 (0.02)	0.383 (0.01)	t(60.4 [†])=-3.5, p=0.0009
White Matter Hyperintensity Burden *	0.002 (0.003)	0.0007 (0.0009)	t(69.2 [†])=1.5, p= 0.14

* Log(X) transformation used for analyses. Means and standard deviations reported in original units

[†] Satterwaithe method for unequal variances

YMRS: Young Mania rating Scale; HDRS: Hamilton Depression Rating Scale

Table 2
Correlations among demographic and clinical variables with measures of cognition and brain integrity

Pearson Correlation Coefficients Prob > r under H0: Rho=0 Number of Observations				
	Global Cognitive Function	Total Gray Matter Volume	Whole Brain Mean FA	nWMH*
Li Duration (years)*	0.165, p=0.22	-0.033, p=0.80	0.363, p=0.005	-0.342, p=0.009
Age	-0.501, p<0.0001	-0.381, p=0.003	-0.518, p<0.0001	0.541, p<0.0001
Education	0.564, p<0.0001	0.136, p=0.31	0.227, p=0.09	-0.335, p=0.01
Gender (Female)	-0.121, p=0.37	0.118, p=0.38	-0.077, p=0.56	0.127, p=0.34
Race (Caucasian)	0.253, p=0.06	0.048, p=0.72	0.217, p=0.10	0.086, p=0.52
YMRS score	-0.004, p=0.98	0.111, p=0.41	0.050, p=0.71	0.004, p=0.98
HDRS 17-item score	0.209, p=0.11	0.156, p=0.24	0.109, p=0.42	0.078, p=0.56
Framingham Stroke Risk Profile	-0.482, p=0.0001	-0.266, p=0.04	-0.420, p=0.001	0.381, p=0.003
Cumulative Illness Rating Scale: Total	-0.058, p=0.67	-0.120, p=0.37	-0.224, p=0.09	0.240, p=0.07
Count	-0.068, p=0.61	-0.061, p=0.65	-0.160, p=0.23	0.240, p=0.07
Cognitive Domains: Global	-----	0.299, p=0.02	0.533, p<0.0001	-0.466, p=0.0002
Visual	0.873, p<0.0001	0.141, p=0.29	0.489, p<0.0001	-0.421, p=0.001
Memory	0.774, p<0.0001	0.207, p=0.12	0.382, p=0.003	-0.486, p=0.0001
Language	0.694, p<0.0001 [N=57]	0.199, p=0.14 [N=57]	0.323, p=0.01 [N=57]	-0.166, p=0.22 [N=57]
Speed/Executive	0.893, p<0.0001	0.378, p=0.003	0.532, p<0.0001	-0.384, p=0.003
Total Gray Matter Volume (normalized)	0.299, p=0.02	-----	0.340, p=0.009	-0.102, p=0.44
Overall White Matter Integrity (Fractional Anisotropy)	0.533, p<0.0001	0.340, p=0.009	-----	-0.382, p=0.003
White Matter Hyperintensity Burden*	-0.466, p=0.0002	-0.102, p=0.44	-0.382, p=0.003	-----

* Log(X) transformation used for analyses

YMRS: Young Mania rating Scale; HDRS: Hamilton Depression Rating Scale

Table 3
Multivariate regressions in BD subjects

Model	Beta (standard error), p-value; standardized beta
Outcome:	Global Cognition
	F(2, 55)=26.6, p<0.0001, R ² =0.49
Intercept	-12.5 (2.0), p<0.0001
Overall White Matter Integrity (Fractional Anisotropy)	24.5 (5.7), p<0.0001; stb=0.43
Education	0.180 (0.04), p<0.0001; stb=0.47
Outcome:	Overall White Matter Integrity (Fractional Anisotropy)
	F(2, 55)=16.4, p<0.0001 R ² =0.37
Intercept	0.433 (0.02), p<0.0001
Lithium Duration (years)	0.0006 (0.0002), p=0.004; stb=0.33
Age	-0.001 (0.0002), p<0.0001; stb=-0.49
Outcome:	White Matter Hyperintensity Burden
	F(1, 56)=23.1, p<0.0001, R ² =0.29
Intercept	-12.8 (1.2), p<0.0001
Age	0.088 (0.02), p<0.0001; stb=0.54

* Log(X) transformation used for analyses